Crossmark

Enhanced Efficacy and Safety: Cabazitaxel Nanodispersions as a Novel Therapeutic Platform against Prostate Cancer

Crossref DOI link: https://doi.org/10.1208/s12249-025-03286-2

Published Online: 2025-12-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Youfa https://orcid.org/0009-0006-6879-8479
Kuang, Yanting https://orcid.org/0009-0001-6127-609X
Chen, Hang https://orcid.org/0009-0002-7724-8066
Zhou, Junyi https://orcid.org/0009-0006-1571-3531
Guo, Bingjie https://orcid.org/0009-0006-3102-535X
Shu, Ruobei https://orcid.org/0009-0007-5992-6405
Wu, Jiali https://orcid.org/0009-0009-1797-4059
Tai, Zongguang https://orcid.org/0000-0001-5603-745X
Wu, Xin https://orcid.org/0000-0003-2875-355X
License Information

Text and Data Mining valid from 2025-12-05

Version of Record valid from 2025-12-05
More Information

Article History

Received: 3 July 2025

Accepted: 24 October 2025

First Online: 5 December 2025

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.